2024-05-20 05:43:01 ET
Summary
- Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism.
- The company's Q1 showed accelerating revenue growth, but guidance offered little new information.
- A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance.
- Still, with the stock trading at a valuation discount, I continue to buy ESPR in expectation of significant upside once the company shows evidence of exponential growth and healthy profitability.
President and CEO of Esperion Therapeutics, Inc. (ESPR), Sheldon Koenig, promised that the company would secure FDA approval of an expanded label for its flagship drugs NEXLETOL and NEXLIZET. Esperion delivered . Koenig promised that the company would secure a patent extension for Bempedoic Acid, a key ingredient in its drugs Esperion delivered . These two achievements were key foundations for the company's sales ambitions to go after a presumed 70M total addressable patient population....
Read the full article on Seeking Alpha
For further details see:
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock